Skip to content

US · IMNN · BIOTECHNOLOGY

Imunon, Inc. (IMNN) intrinsic value and stock valuation

$0.54as of 2026-11-21 · Mkt cap 4.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Imunon, Inc. DCF and intrinsic value

InvestorsCraft values IMNN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMNN’s statements →

Imunon, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lawrenceville, NJ 08648 imunon.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-14.49M
20112025
Free cash flow
-$-14.18M
20112025
Total equity
$7.06M-17.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$500K$500K
Operating income-$-14.65M-$-19.13M-$-21.03M-$-24.92M-$-21.01M
Net income-$-14.49M-$-18.62M-$-19.51M-$-35.9M-$-20.77M
EPSd-$-6.83M-$-21.16M-$-28.28M-$-65.27M-$-692.33M
Operating cash flow-$-13.9M-$-18.85M-$-19.02M-$-23.1M-$-16.22M
Capital expenditure-$-280K-$-30K-$-450K-$-270K-$-310K
Free cash flow-$-14.18M-$-18.88M-$-19.47M-$-23.36M-$-16.54M
Total assets$12.3M$9.72M$21.9M$44M$74.1M
Total debt$1.01M$1.14M$1.62M$6.27M$6.63M
Net debt-$-7.77M-$-4.73M-$-4.21M-$-5.23M-$-12.95M
Total equity$7.06M$4.24M$13.4M$29.3M$55.8M
Cash and short-term investments$8.78M$5.87M$15.7M$32.8M$49.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$500K$500K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$500K$500K
Research and development expenses$7.78M$11.6M$11.3M$11.7M$10.6M
Selling, general and administrative expenses$6.87M$7.49M$9.74M$13.7M$10.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$14.7M$19.1M$21M$25.4M$21.5M
Cost and expenses$14.7M$19.1M$21M$25.4M$21.5M
Interest income$160K$450K$730K$500K$20K
Interest expense$0.00$0.00$200K$5.03M$570K
Depreciation and amortization$700K$720K$720K$730K$700K
Ebitda-$-13.8M-$-17.9M-$-19.88M-$-31.71M-$-20.88M
Operating income-$-14.65M-$-19.13M-$-21.03M-$-24.92M-$-21.01M
Total other income/expenses, net$160K$510K$240K-$-12.54M-$-1.15M
Income before tax-$-14.5M-$-18.62M-$-20.8M-$-37.47M-$-22.15M
Income tax expense$0.00$0.00-$-1.28M-$-1.57M-$-1.38M
Net income-$-14.49M-$-18.62M-$-19.51M-$-35.9M-$-20.77M
Weighted average shares outstanding$2.12M$880K$690K$550K$30K
Weighted average diluted shares outstanding$2.12M$880K$690K$550K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$8.78M$5.87M$15.7M$32.8M$49.4M
Net receivables$0.00$0.00$0.00$130K$110K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$10.7M$8.01M$18.2M$36.8M$52M
Property, plant and equipment, net$1.56M$1.66M$2.35M$700K$1.17M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$13.4M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.56M$1.71M$3.68M$7.2M$22.1M
Total assets$12.3M$9.72M$21.9M$44M$74.1M
Accounts payable$1.39M$1.3M$3.52M$3.59M$2.55M
Short-term debt$410K$450K$490K$1.66M$550K
Deferred revenue$0.00$0.00$0.00$0.00$500K
Total current liabilities$4.62M$4.79M$7.39M$10M$6.77M
Long-term debt$600K$690K$1.14M$4.61M$6.09M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$600K$690K$1.14M$4.61M$11.5M
Capital lease obligations$410K$1.14M$1.62M$230K$780K
Total liabilities$5.23M$5.47M$8.53M$14.7M$18.3M
Common stock$30K$150K$90K$70K$60K
Retained earnings-$-421.3M-$-406.8M-$-388.18M-$-368.67M-$-332.77M
Accumulated other comprehensive income (loss)$0.00$0.00$60K$30K-$-10K
Total equity$7.06M$4.24M$13.4M$29.3M$55.8M
Total investments$0.00$0.00$9.86M$21.3M$29.8M
Total debt$1.01M$1.14M$1.62M$6.27M$6.63M
Net debt-$-7.77M-$-4.73M-$-4.21M-$-5.23M-$-12.95M
Cash flow statement
20252024202320222021
Net income-$-14.5M-$-18.62M-$-19.51M-$-35.9M-$-20.77M
Depreciation and amortization$700K$720K$720K$730K$700K
Stock-based compensation$130K$480K$760K$2.67M$3.76M
Change in working capital-$-330K-$-2.65M-$-2.07M$1.89M-$-970K
Accounts receivable$0.00$0.00$70K-$-20K-$-110K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00-$-3.06M$0.00$1.04M$300K
Net cash provided by operating activities-$-13.9M-$-18.85M-$-19.02M-$-23.1M-$-16.22M
Investments in property, plant and equipment-$-280K-$-30K-$-450K-$-270K-$-310K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-280K$9.83M$11M$8.28M-$-30.12M
Common stock issued$17.1M$9.06M$2.78M$6.72M$52.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-10K$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.1M$9.06M-$-3.64M$6.72M$54.8M
Net change in cash$2.91M$30K-$-11.65M-$-8.09M$8.42M
Cash at end of period$8.78M$5.87M$5.84M$17.5M$25.6M
Operating cash flow-$-13.9M-$-18.85M-$-19.02M-$-23.1M-$-16.22M
Capital expenditure-$-280K-$-30K-$-450K-$-270K-$-310K
Free cash flow-$-14.18M-$-18.88M-$-19.47M-$-23.36M-$-16.54M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Imunon, Inc.

        Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.

        CEO
        Stacy R. Lindborg
        Employees
        20
        Beta
        1.95

        Explore

        Frequently asked questions

        What is the intrinsic value of Imunon, Inc. (IMNN)?

        InvestorsCraft does not currently publish an intrinsic value for IMNN. How the IC value is calculated.

        Is IMNN undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMNN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.